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BACKGROUND: A dose-finding study was performed to evaluate the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD) and
the recommended dose (RD) of escalating the doses of capecitabine and fixed doses of irinotecan and oxaliplatin on a biweekly
schedule for metastatic colorectal cancer patients (mCRC). A pharmacogenomic analysis was performed to investigate the
association between SNPs and treatment outcome.
METHODS: Eighty-seven chemotherapy-naı ¨ve mCRC patients were recruited through a two-step study design; 27 were included in the
dose-finding study and 60 in the pharmacogenomic analysis. Oxaliplatin (85mgm
-2) and CPT-11 (150mgm
-2), both on day 1, and
capecitabine doses ranging from 850 to 1500mgm
-2 bid on days 1–7 were explored. Peripheral blood samples were used to
genotype 13 SNPs in 10 genes related to drug metabolism or efficacy. Univariate and multivariate Cox analysis was performed to
examine associations between SNPs, ORR and PFS.
RESULTS: The capecitabine RD was 1000mgm
 2 bid. Diarrhoea and neutropenia were the DLTs. After a median follow-up of 52.5
months, the median PFS and OS were 12 (95% CI; 10.6–13.4) and 27 months (95% CI; 17.2–36.8), respectively.
The GSTP1-G genotype, the Ko ¨hne low-risk category and use of a consolidation approach strongly correlated with decreased risk of
progression. Patients with all favourable variables showed a median PFS of 42 months vs 3.4 months in the group with all adverse
factors. A superior clinical response was obtained in patients with one GSTP1-G allele as compared with GSTP1-AA carriers
(P¼0.004).
CONCLUSION: First-line therapy with oxaliplatin, irinotecan and capecitabine is efficient and well-tolerated. The GSTP1 polymorphism
A4G status was significantly associated with ORR and PFS in mCRC treated with this triplet therapy.
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Colorectal cancer (CRC) is one of the most common malignancies
and the second leading cause of death from cancer in Europe and
North America. It is responsible for approximately 1 million new
cases and half a million deaths per year, worldwide (Bray et al,2 0 0 2 ) .
Relevant advances have been made in the last years in the
treatment of this disease, essentially owing to the introduction
of combination chemotherapy regimens containing oxaliplatin
(L-OHP) and irinotecan (CPT-11) (Kelly and Goldberg, 2005).
Addition of either drug to 5-fluorouracil plus leucovorin (5-FU/
LV) significantly increased both objective tumour response
rate (ORR) and prolonged overall survival (OS) (de Gramont
et al, 2000; Saltz et al, 2000). More recently, a triplet combination
of 5-FU, L-OHP and CPT-11 has emerged as a feasible and highly
active regimen for mCRC patients. We (Calvo et al, 2002a,b) and
others (Comella et al, 2002; Falcone et al, 2002) had previously
reported a consistently high response rate and prolonged survival
times with varying doses and schedules of this triplet regimen.
Pooled results of large-scale, phase-III trials have shown that
first-line treatment of mCRC with capecitabine, an oral fluoropyr-
imidine pro-drug (Miwa et al, 1998), provided advantages over
intravenous 5-FU/LV in terms of response rate and safety profile,
with equivalent survival times (Hoff et al, 2001; Van Cutsem et al,
2001). Subsequently, several phase I and phase II trials tested
capecitabine as the combination partner for L-OHP (Cassidy et al,
2004), CPT-11 (Tewes et al, 2003) or both (Souglakos et al, 2003),
with preliminary promising results in terms of efficacy and a
predictable toxicity profile.
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aim: first to determine the optimal dose of capecitabine in
combination with L-OHP and CPT-11 as first-line therapy for
mCRC patients. The second objective was to identify potential
polymorphisms related to a better and safer outcome.
In this study we report, after a significant long-term follow-up,
the effect of both clinical and molecular parameters on the
outcome of chemotherapy-naı ¨ve mCRC patients treated with this
triplet regimen. We propose a combined clinical and pharmaco-
genomic assessment to identify which patients could benefit from
this efficient regimen.
MATERIALS AND METHODS
We initially performed a dose-finding study of escalating doses of
capecitabine with biweekly fixed doses of CPT-11 and L-OHP in
patients with mCRC to determine the dose-limiting toxicity (DLT),
maximum-tolerated dose (MTD) and recommended dose (RD).
Additional research was conducted to determine the activity and
toxicity profile of the RD and to investigate the association
between genetic polymorphisms and treatment outcome in terms
of response rate and progression-free survival (PFS).
Eligibility
All eligible patients had histologically confirmed mCRC not
amenable to curative surgery, age between 18 and 75 years, an
Eastern Cooperative Oncology Group (ECOG) performance status
score of 0–2 and a life expectancy 412 weeks. In addition,
adequate organ function was required as indicated by an absolute
neutrophil count 41.5 10
9/l, a platelet count 475 10
9/l, serum
creatinine o1.3mgdl, serum bilirubin o1.25 times the normal
upper limit (UNL) and serum transaminases o3.0 times UNL. The
exclusion criteria included active second malignancy (except for
non-melanoma skin cancer or in situ cervical cancer), sympto-
matic metastases in the central nervous system or carcinomatous
leptomeningitis, uncontrolled severe infection, major organic
failure, ischemic cardiopathy, active inflammatory bowel disease
or chronic diarrhoea syndrome, bowel obstruction or prior
extensive pelvic radiotherapy.
Pretreatment baseline evaluation included a complete medical
history, physical examination, full blood count, biochemistry,
including carcinoembrionic antigen, and a CT scan of the chest,
abdomen and pelvis. During treatment, a physical examination
and blood cell counts were performed biweekly. Treatment was
delayed until recovery in the case of neutrophil level o1500/mm
3,
platelet level o75000/mm
3 or diarrhoea or stomatitis grade 41o n
the planned day of treatment. If treatment had to be delayed for
longer than 2 weeks, or any drug discontinued permanently,
patients were excluded from the study. In the case of grade-3 to
grade-4 adverse events, treatment was continued after resolution of
the event using doses of L-OHP, CPT-11 and capecitabine reduced
by 25%, except in the case of grade 3/4 diarrhoea, when only
CPT-11 and capecitabine doses were reduced by 25%. The
L-OHP dose was reduced by 25 or 50% in patients with grade-2
or grade-3 peripheral neuropathy, respectively. The capecitabine
dose was reduced by 25% in case of grade 3/4 stomatitis and/or
Hand-Foot Syndrome.
Patients’ characteristics and their outcomes were unknown to
investigators performing genetic analyses. The local institutional
review board approved the study and all patients provided written
informed consent before recruitment.
Study design and treatment
Between April 2004 and October 2008, a total of 87 mCRC patients
were enrolled in a two-step study.
Step-1. Dose-finding study
Treatment consisted of escalating doses of capecitabine starting
from the evening of day 1 to day 7, in association with fixed
biweekly doses of L-OHP (85mgm
 2 infused over 2h) immedi-
ately followed by CPT-11 (150mgm
 2 infused over 90min). The
L-OHP and CPT-11 doses and schedule were based on in vitro
synergistic activity and on phase-I clinical trials combining the two
drugs every two weeks, (Goldwasser et al, 2000), with a planned
initial CPT-11 dose reduction due to the expected overlapping
gastrointestinal toxicity with the addition of capecitabine. The
planned dose levels of capecitabine were 850, 1000, 1250, and
1500mgm
-2, twice a day (Supplementary Table 1). Consecutive
cohorts of at least three patients were included sequentially in each
dose level, and no intra-patient dose escalation was allowed. If one
out of three patients experienced a DLT, a minimum of three
additional patients was enrolled at the same dose level. MTD was
defined if two out of three or four out of six patients experienced a
DLT. The recommended dose was the dose level just below the MTD.
All toxicities experienced during the study were recorded and
graded according to the National Cancer Institute–Common
Toxicity Criteria (NCI–CTC). DLT was defined as grade-4
neutropenia lasting more than 7 days, grade 3/4 neutropenia
associated with fever 4381C, grade-4 thrombocytopenia,
symptomatic thrombocytopenia (haemorrhage), and grade 3/4
non-haematological toxicity, except for alopecia, nausea or
vomiting.
Step-2. Clinical and pharmacogenomic analysis
Once the capecitabine RD was established in a limited dose-finding
assessment, this cohort was further expanded to prospectively
perform an exploratory pharmacogenomic profiling of the triplet
combination. The sites of metastatic disease were radiologically
re-evaluated every 8 weeks according to standard RECIST criteria
unless clinically otherwise indicated (Therasse et al, 2000). At the
time of maximum response, determined by serial CT scans or
Positron Emission Tomography (PET) if clinically indicated,
patients were evaluated by a multidisciplinary team that included
surgeons, medical oncologists, hepatologists and interventional
radiologists. In this evaluation it was ruled out whether a
consolidative approach (CA) should be attempted. These
approaches consisted of surgical removal of all macroscopic
remaining disease, radiofrequency ablation, liver radioembolisa-
tion using Yttrium
90 microspheres or cytoreductive surgery with
hypertermic intraperitoneal chemotherapy (HIPEC).
Genotyping
Genomic DNA was extracted from 200ml of whole blood using the
DNA Isolation Kit-I from MagNa Pure LC (Roche, Barcelona,
Spain) according to the protocols provided by the manufacturer.
Thirteen polymorphisms in 10 genes related to drug metabo-
lism, involved in DNA repair or target of chemotherapy agents,
were selected from various reports as being potentially predictive
of oxaliplatin, fluoropyrimidines or irinotecan efficacy, and/or
toxicity. The primer sequences and analysis technique are listed in
Supplementary Table 3.
Some polymorphic regions were analysed by PCR-RFLP
(restriction fragment length polymorphism) technique. Digestions
were performed in a final volume of 50ml, containing 20ml of PCR
product. Appropriate units of the corresponding enzymes were
added to the other components provided by New England Biolabs
(NEB, Beverly, MA, USA). After restriction enzyme digestion,
fragments were visualised on a 2–3% agarose or LM-Sieve gel
(Pronadisa, Madrid, Spain). Furthermore, one sample for each of
the genotypes obtained by the RFLP technique was confirmed by
direct sequencing the polymorphic region of each gene. No
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the GSTT1 and GSTM1 genes was tested simultaneously using
allele-specific sequence primers through a multiplex PCR protocol,
according to the method previously described (Kim et al, 2000),
with slight modifications. The albumin gene was used as positive
control in each reaction. Analysis of the A(TA)nTAA motif in the
promoter region of the UGT1A1 gene was performed by PCR,
according to previous protocol (Monaghan et al, 1999), followed
by automated sequencing analysis of the purified PCR products
using an automated sequencer (ABI PRISM 3130XL DNA
Sequencer; Applied Biosystems, Madrid, Spain).
The ERCC1-118 genotypes were determined using a TaqMan
Allelic Discrimination Assay (Applied Biosystems, Foster City, CA,
USA; C_8901525_10) according to the manufacturer’s instructions.
Briefly, 10ng of DNA were added to 25ml of reaction containing
forward and reverse primers along with two allele-specific labelled
probes.
The number of 28-bp tandem repeats (2R or 3R) in the TYMS
gene and the associated G4C SNP was performed as previously
described (Kawakami and Watanabe, 2003; Mandola et al, 2003;
Lincz et al, 2007). The polymorphism (G4C) in 50-UTR region
changes a crucial residue in the upstream stimulatory factor (USF)
E-box consensus elements, abolish this USF binding and alter
transcriptional activity. The classification of TYMS allele was based
on the number of functional USF, consensus elements, in this
5 polymorphic region (Lincz et al, 2007). In our study, the most
frequent allele was two and three USF sites (63 and 30%,
respectively), whereas one or four USF sites were founded in only
2.7 and 4% of the patients, respectively. The favourable TYMS-
50-UTR genotype included those genotypes that have been linked
to decreased TYMS expression (2C/2C, 2C/3C, 2GC/3C, 2C/3G,
3C/3C). On the contrary, unfavourable groups included three
repeat genotypes with a G allele (2GC/3G, 3G/3C, 3G/3G). These
genotypes were considered as a single class when statistical
analysis was performed.
Statistical analysis
A descriptive statistical methodology was used to design and
analyse the dose escalation study. An exploratory pharmaco-
genomic analysis was conducted as an extension of the recom-
mended dose level, where the primary endpoint was to correlate
genetic polymorphisms with ORR and PFS. Secondary endpoints
were aimed at finding out associations between SNPs, toxicity
profile and OS. To calculate the sample size of the pharmaco-
genomic study, the expected frequency of unfavourable genotypes
and its effect on RR and DFS was assessed. A Simon two-stage
phase-II clinical trial design enrolling a minimum of 35 (stage-1)
and a maximum of 60 eligible patients (stage-2) was chosen to get
at least 25% of GSTP1-AA patients with a difference in terms of
PFS greater that 1.5-fold with respect to genotypes harbouring any
G-allele. With the significance level set at 0.05, the power to detect
these differences was 80%.
Progression-free survival and OS were calculated from the first
day of treatment to the date of first observation of progressive
disease, death or last contact. Patients without progression at the
time of the analysis were censored at their last available follow-up
assessment. The log-rank test and Kaplan–Meier plots were used
to evaluate the impact of genotypes on PFS.
Contingency tables and w
2-tests were used to check the
association of response or toxicity with the polymorphic genes
analysed. All P-values were two-sided. Compare2 from the
WINPEPI program, version 1.42 (Copyright J.H. Abramson,
2003-5, part of the PEPI suite of computer Programs for
EPIdemiologists), was used when the w
2-tests did not fulfil the
analysis condition based to Cochran rule: If a w
2-test frequencies
expected are 1 or less in more than 20% of the square, exact test
2 K tables of PEPI program can be used.
The hazard ratio (HR) of clinical response and/or toxicity of the
most relevant polymorphisms and patient outcome were assessed
using Cox proportional hazard models using the reverse method.
The model was adjusted taking into consideration relevant clinical
parameters according to the univariate analysis and use of any
consolidation approach that may likely influence on survival times
(Gray et al, 2001; Verwaal et al, 2003, 2008; Adam et al, 2004;
Poston et al, 2005). Confidence intervals (CIs) were within 95%.
All statistical tests were conducted using the SPSS software v15.0
for Windows (SPSS Inc., Chicago, IL, USA). Probability values
(P-values) lower than 0.05 were considered statistically significant.
RESULTS
Dose finding study
The number of patients in each dose level and the type of DLTs are
summarised in Supplementary Tables 1 and 2. The starting dose
level was L-OHP 85mgm
 2, CPT-11 150mgm
 2 and capecitabine
850mgm
 2, twice a day. At this initial dose level, grade-4
neutropenia lasting 47 days was recorded in one patient; so six
more patients were included in this cohort. Only one out of these
six patients presented with DLT (grade-4 diarrhoea and grade-3
febrile neutropenia). Three patients entered into the second dose
level, and no DLT was observed. Dose escalation proceeded to
dose level-3 (capecitabine 1250mgm
 2, twice a day). Two of three
patients treated at this level developed DLT: grade-4 diarrhoea and
grade-3 febrile neutropenia (one patient), and grade-4 diarrhoea
with grade-3 asthenia (one patient). The RD was therefore
established at dose level-2. This dose level was subsequently
expanded, with only one of the 12 additional patients experiencing
a DLT (grade-3 diarrhoea), (Supplementary Table 2).
Clinical and pharmacogenomic analysis
In the second part of the study, 63 additional mCRC patients were
subsequently treated with L-OHP 85mgm
 2, CPT-11 150mgm
 2
and capecitabine 1000mgm
 2, twice a day on days 1–7.
Genotyping analysis was successful in 60 out of 63 patients.
The clinicopathological characteristics of these patients are
summarised in Table 1. Most of them had an ECOG 0–1, were
classified as low- or intermediate-risk patients according to Ko ¨hne
classification and had a low tumour burden (the median number
of metastatic sites was 1). The median number of cycles
administered was seven, with 26 patients receiving more than
eight cycles.
The toxicity profile of the combination is listed in Table 2. The
most common severe haematological toxicity was grade 3/4
neutropenia in 27% of the patients. Gastrointestinal disturbances
were mild, although grade 3/4 diarrhoea and emesis were noted
in 11 and 5% of the patients, respectively. Grade 1/2 neurosensory
toxicity was developed in 67% of the patients, with only
2% reported as severe. Sixteen patients (26.7%) required a
dose reduction and a dose delay was registered in 21 patients
(35%).
On an intent-to-treat basis we observed a 66.6% ORR with 38
(63.3%) PR and 3 (3.3%) CR. Clinical response (CR, PR, and SD
lasting 46 months) was achieved in 75% of the patients. Twenty-
eight patients (46.7%) received a consolidation approach, includ-
ing liver surgery (20 patients), liver radioembolisation with
Yttrium
90 microspheres (4 patients), liver radiofrequency ablation
(1 patient) and peritonectomy with HIPEC (3 patients).
After a median follow-up of 52.5 months (range: 40.5–62.4), the
median PFS and OS were 12 (95 % CI; 10.6–13.4) and 27 months
(95 % CI; 17.2–36.8), respectively. Five-year PFS and OS were 10.4
and 23.9%, respectively.
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cies were similar to those expected according to the Hardy–
Weinberg equilibrium (data no shown).
Distribution of genotypes and response to chemotherapy are
summarised in Table 3. For association analysis, responding
patients were those with CR, PR, or SD lasting 46 months,
whereas patients with SD less than 6 months were referred to as
non-responders.
In univariate analysis, only GSTP1-variant (GG) was signifi-
cantly related to response (P¼0.007, w
2; Table 3, in bold).
According to previous studies (Stoehlmacher et al, 2004) patients
were classified as having a favourable genotype (homozygous
variant GG and heterozygous AG) or an unfavourable genotype
(homozygous AA). Patients harbouring at least one GSTP1-G allele
showed significantly better clinical response rate as compared with
patients with the GSTP1-AA genotype (79.5 vs 20.5%, P¼0.004).
None of the other genotypes analysed were significantly associated
with treatment response. Among clinical parameters, only Ko ¨hne
risk index (Ko ¨hne et al, 2002) was significantly associated with
response (Table 1). Multivariate analysis showed GSTP1 as the
only significant predictor of response (P¼0.002).
Genetic determinants and toxicity. For statistical analysis, overall
toxicity was dichotomised as either moderate (grades 1–2) or
severe (grades 3–4). Given the low incidence of severe adverse
events we also tested genotype associations with grade 2/3 toxicity.
Statistical analyses were performed by either considering each
toxicity individually or by grouping them in three main categories:
haematological, gastrointestinal and other.
No statistically significant differences with respect to toxicity
were observed according to relevant clinical variables. Never-
theless, older patients (61–70 years) were more likely to develop
grade-3 to grade-4 haematological and non-haematological toxicity
(data no shown).
Considering toxicities on an individual basis, patients with
the MTHFR c.1298 A/A genotype were more likely to develop
grade 3/4 neutropenia (P¼0.035). A significant association was
also observed between the UGT1A1 6/7 genotype and grade 3/4
anaemia (P¼0.031).
When grouped toxicities were considered, we found a statisti-
cally significant association between haematological toxicity and
both UGT1A1-6/7 and MTHFR c.1298 A/A genotypes (P¼0.034;
Table 1 Baseline characteristics of patients included in the pharmacogenomic analysis
Clinical response
TTP OS
Variables n (%)
Responder
(CR+PR+SD46
months)
Non-responder
(SD o6 months) P
a
Median
(95% CI) P
b
Median
(95% CI) P
b
Age (years; range) 58 (37–75) n (%) n (%)
o60 35 (56.5) 25 (71) 10 (29) 0.55 12 (8.1–15.8) 0.69 29 (14.5–43.6) 0.79
X60 27 (43.5) 20 (80) 5 (20) 12 (10.9–13.2) 24 (21–27)
Gender
Male 45 (75) 33 (73) 12 (27) 0.74 12 (10.9–13.2) 0.9 27 (17.6–36) 0.38
Female 15 (25) 12 (80) 3 (20) 9.8 (3.3–16.4) 24 (7.3–41.5)
ECOG performance status
0–1 54 (90) 39 (72) 15 (28) 0.26 12 (10.4–13.5) 0.79 27 (17.2–36.7) 0.31
2 6 (10) 6 (100) — 12 (8.7–15) 15 (0.0–34.3)
Ko ¨hne risk classification
Low 26 (43) 22 (85) 4 (15) 0.04 15 (8.7–21.2) 0.001 35.7 (—) 0.001
Intermediate 28 (47) 21 (75) 7 (25) 11 (7.7–14.9) 24 (18.5–29.1)
High 6 (10) 2 (33) 4 (67) 3 (1.3–5.1) 5 (3–6.8)
Primary tumour site
Colon 41 (68) 28 (68) 13 (32) 0.11 12 (9.2–14.6) 0.33 24 (21.3–27.4) 0.09
Rectum 19 (31) 17 (89) 2 (11) 13 (10.5–15.4) 43 (25.1–61.4)
Previous radiotherapy 6 (10) 5 (83) 1 (17) 1 8 (5.3–9.8) 0.23 18 (16.1–29.6) 0.9
Previous adjuvant chemotherapy 12 (20) 10 (83) 2 (17) 0.71 9.8 (4.6–15.1) 0.31 19 (9.1–29.5) 0.9
Consolidation
Yes 28 (48) — — — 17 (12.2–21.4) 0.001 56 (32.9–79) 0.001
No 30 (52) — — 7 (5.8–7.6) 14 (5.1–22.7)
Dose reduction 16 (27) 11 (69) 5 (31) 0.51 12 (4.8–19.2) 0.46 24 (12.7–35.8) 0.31
Dose delay 21 (35) 14 (67) 7 (33) 0.35 9.8 (2.2–17.4) 0.15 18 (4.8–31.9) 0.21
Abbreviations: CI¼confidence interval; CR¼complete response; ECOG¼Eastern Cooperative Oncology Group; OS¼overall survival; PR¼partial remission; SD¼stable
disease.
aClinical response calculated from w
2-test. Kaplan–Meier estimates of TTP and OS.
bDifference of the estimates tested using the log-rank test.
Table 2 Toxicity profile of the triplet combination
Grade
Adverse event 1 (n,% ) 2( n,% ) 3( n,% ) 4( n,% )
Leucopenia 15 (25) 20 (33) 2 (3) 3 (5)
Neutropenia 8 (13) 14 (23) 13 (22) 3 (5)
Anaemia 32 (53) 12 (20) 2 (3) —
Thrombocytopenia 11 (18) — 2 (3) —
Vomiting 22 (37) 17 (28) 3 (5) —
Diarrhoea 9 (15) 25 (42) 5 (8) 2 (3)
Mucositis 11 (18) 8 (13) 1 (2) —
Asthenia 15 (25) 24 (40) 3 (5) —
Neurotoxicity 25 (42) 15 (25) 1 (2) —
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cantly related to UGT1A1 6/7 and 7/7 genotypes when toxicity
grades were dichotomised between 0–1 and 2–4 (P¼0.005) (data
not shown). Development of gastrointestinal toxicity was also
significantly related to UGT1A1-6/7 (P¼0.001) and MTHFR
c.1298-AA (P¼0.023). A tendency to develop other non-haema-
tological toxicities was also related to the MTHFR c.1298 AA
genotype (P¼0.079).
Genetic determinants and survival. In the univariate analysis, of
all clinical prognostic factors considered, only Ko ¨hne risk
classification and consolidation approach were related to TTP
and OS (Table 1).
A significantly higher risk of progression was associated with
the GSTP1-AA genotype in the univariate analysis. Median PFS
was 6.3 months for AA patients as compared with 12.7 months
in the G-containing genotype patients (P¼0.003) (Figure 1A;
Table 4).
In the multivariate model, the GSTP1-G allele, the Ko ¨hne low-
risk category and use of a consolidation approach were all
associated with decreased risk of progression (Table 4) and were
subsequently considered as favourable factors for further analyses.
Patients with all favourable variables showed a median PFS of 42
months (95% CI; 5.8–78) vs 3.4 months (95% CI; 2.5–4.3) in the
group with all adverse factors (GSTP1-AA, intermediate- or high-
risk group according to Ko ¨hne classification and no consolidation
approach) (Po0.001) (Figure 1B).
Finally, we sought to assess the influence of GSTP genotyping on
the significant clinical variables in the multivariate model.
Combined analysis of GSTP1-G allele with either consolidation
therapy (Supplementary Table 4) or Ko ¨hne classification (Supple-
mentary Table 5) was statistically significant when the different
group of options were analysed.
Statistical differences were observed when OS was assessed
according to the possibility of performing a consolidation
approach (5-year OS; 39.5% vs 11.4%, P¼0.001) or Ko ¨hne
classification (5-year OS of 50.5% vs 0% for patients in the
low- and high-risk category, respectively). In addition, 5-year OS
was significantly longer for patients with the GSTP1-G genotype
(25% vs 16%, P¼0.02).
DISCUSSION
In this study, we have shown that the biweekly combination of
L-OHP, CPT-11 and capecitabine is a feasible and active
regimen, with neutropenia and diarrhoea as the DLT. The RD of
capecitabine coincides with that recently reported by other authors
with this same combination (Vasile et al, 2009). Neutropenia was
frequently observed, although it was usually short-lived and rarely
complicated. These findings are in contrast to those reported by
Bajetta et al (2007) where no grade 3/4 neutropenia was reported.
The different capecitabine dose (1000mg/m
2/day on days 2–6)
might partly explain these discrepancies. Reported incidence of
grade 3/4 diarrhoea in previous studies with this same triplet
combination is 25–30%, (Masi et al, 2004; Bajetta et al, 2007) with
CPT-11 doses of 165–180mgm
 2 every two weeks. The lower
CPT-11 dose used in our study may be partly responsible of the
two-fold decrease in the incidence of severe diarrhoea, without
apparently compromising efficacy.
To the best of our knowledge, this is the first trial to explore the
association between SNPs with a potential influence on L-OHP,
CPT-11 and capecitabine and the clinical outcome with the use of a
triplet cytotoxic regimen. So far, conflicting clinical findings exist
regarding the predictive role of XPD-751, the combination of
favourable genotypes within the TYMS-50 and ERCC1 polymorph-
isms, and the efficacy of fluoropyrimidine/oxaliplatin-based
chemotherapy (Stoehlmacher et al, 2004; Ruzzo et al, 2007;
Table 3 Distribution of genotypes according to response
Responder
(CR+PR+SD4
6 months)
Non-
responder (SD
o6 months)
Total
n (%) n (%) n (%) P-value
All 60 (100) 45 (75) 15 (25) —
0.28
TS-5-UTR
2R/2R 10 (16) 5 (50) 5 (50)
2R/3R 31 (52) 23 (74) 8 (26)
3R/3R 19 (32) 15 (79) 4 (21)
TS-5-UTR+G/C SNP 0.056
A) 2C/2C,2C/3C,
2GC/3C,2C/3G,3C/3C
35 (61) 23 (66) 12 (34)
B) 2GC/3G,3G/3C,
3G/3G
22 (39) 16 (73) 6 (27)
TS-31494del6 0.26
 6/ 6 6 (10) 5 (83) 1 (17)
 6/+6 26 (43) 21 (81) 5 (19)
+6/+6 28 (47) 19 (68) 9 (32)
GSTP1 0.007
AA 20 (33) 10 (50) 10 (50)
AG 34 (56) 30 (88) 4 (12)
GG 6 (10) 5 (83) 1 (17)
GSTT1 0.1
Present 46 (77) 34 (74) 12 (26)
Null 14 (23) 11 (78) 3 (22)
GSTM1 0.1
Present 25 (42) 21 (84) 4 (16)
Null 35 (58) 24 (68) 11 (31)
GSTA1 0.32
CC 20 (33) 15 (75) 4 (25)
CT 28 (47) 21 (75) 7 (25)
TT 13 (21) 9 (69) 4 (31)
XPD 0.30
AA 23 (38) 18 (78) 5 (22)
AC 30 (51) 21 (70) 9 (30)
CC 7 (11) 6 (86) 1 (14)
XRCC1 0.33
GG 27 (44) 20 (74) 7 (30)
GA 26 (43) 20 (77) 6 (23)
AA 7 (11) 5 (71) 2 (29)
ERCC1–118 0.36
CC 9 (15) 6 (67) 3 (33)
CT 25 (42) 21 (84) 4 (16)
TT 25 (42) 17 (68) 8 (32)
UGT1A1 0.38
5/6 1 (1.6) — 1 (100)
6/6 29 (48) 22 (76) 7 (24)
6/7 28 (47) 21 (75) 7 (25)
7/7 2 (3.3) 1 (50) 1 (50)
MTHFR-677 0.17
CC 26 (43) 18 (69) 8 (31)
CT 23 (38) 17 (74) 6 (26)
TT 11 (18) 10 (91) 1 (9)
MTHFR-1298 0.33
AA 31 (52) 22 (71) 9 (29)
AC 23 (38) 18 (78) 5 (22)
CC 6 (10) 5 (83) 1 (17)
Abbreviations: CR¼complete response; PR¼partial remission; SD¼stable disease;
UTR¼untranslated region.
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British Journal of Cancer (2010) 102(6), 987–994 & 2010 Cancer Research UKMartinez-Balibrea et al, 2008; Pare ´ et al, 2008). In addition, a lack
of association has been reported for the TYMS genotype and
capecitabine-based therapy response (Tsuji et al, 2003; Martinez-
Balibrea et al, 2008). However, our data suggest a role for the
GSTP1 genotype as a predictive marker of clinical response and
PFS. GSTP1-AA has been related with a higher enzymatic capacity
for the conjugation of various cytotoxic drugs and a subsequent
decrease of the cytotoxic effect of chemotherapy on tumour cells
(Shen et al, 1997; O’Brien et al, 2000). Although initial results
suggested longer survival for mCRC patients with the GSTP1-GG
genotype who were treated with second- and third-line FOLFOX
chemotherapy, (Stoehlmacher et al, 2002), more recent trials
(Le Morvan et al, 2007; Ruzzo et al, 2007; Pare ´ et al, 2008) found no
association between GSTP1 variant and PFS. In addition, GSTP1
genotypes showed no clear influence on PFS in mCRC patients
treated with either second-line based on XELOX or capecitabine as
single agent (Kweekel et al, 2008, 2009). By contrast, a growing body
of evidence suggests an association between GSTP1 and CPT-11
activity. In vitro experiments with human cell lines showed that
when levels of nuclear GSTP1 are decreased, colonic HCT8 cells are
partially more sensitive to CPT-11 (Goto et al, 2002). In the clinical
setting (Kweekel et al, 2008), the survival benefit of adding CPT-11 to
capecitabine for treatment of mCRC patients was only observed in
those with the GSTP1-G-containing genotype. The results of this
study seem to support these findings. Our patients harbouring at
least one GSTP1-G allele had a reduced risk of progression of nearly
three-fold and almost doubled the CRR as compared with patients
with the GSTP1-AA genotype.
In an attempt to minimise possible confounding factors, we
included in our analysis clinical parameters clearly related to
patients’ outcome. It is noteworthy that the GSTP1 genotype
had a significant influence on the PFS when these clinical
parameters were also considered. Among patients who underwent
liver surgery, a 5-year OS of 58% was obtained for GSTP1 AG/GG
patients as compared with 0% for those patients who carried
the AA genotype. Patients with the GSTP1-G-containing allele
have also a prolonged median PFS within each of the Ko ¨hne
risk categories. Combination of the GSTP1-G-containing genotype
with the favourable clinical parameters identified patients
who would benefit most from the use of this triplet scheme.
In fact, a remarkable 5-year PFS of 43% was obtained for
patients fulfilling all of these factors. In contrast, a median
PFS of 3.4 and 7.4 months was obtained for patients with none
or one favourable factor, respectively, suggesting that the up-front
use of this triplet cytotoxic therapy may not be an optimal strategy
in this setting. There may be several potential limitations in
these findings. First, the limited sample size makes it mandatory
for data to be confirmed in a larger cohort of patients. Second,
although the Ko ¨hne risk index and the use of a consolidative
approach seem to have a stronger effect on patients’ outcome as
compared with the GSTP genotype, consolidative procedures
cannot be used as a prospective marker for up-front determination
of therapy benefit. Third, despite no differences between the
frequencies of GSTP1 genotypes and patients undergoing
liver surgery or a consolidative procedure were noted, patients
carrying any G-containing allele were more likely to belong to the
Ko ¨hne low- and intermediate-risk categories and therefore to
receive any consolidative procedure as compared with those in the
high-risk group, suggesting that these variables may not be truly
independent.
According to other studies, grade 3/4 gastrointestinal toxicity
was significantly more frequent in patients with the UGT1A1 6/7
genotypes (Liu et al, 2008). Although recent work suggests lack
of association of UGT1A1*28 with irinotecan toxicity (Braun
et al, 2009), the low incidence of the 7/7genotype (two patients)
in our study precludes any firm conclusion. Our data also
suggest that the MTHFR1298-AA is related to neutropenia
and gastrointestinal toxicity. The link between this MTHFR
polymorphism and toxicity remains controversial. Even if
our results are not in agreement with previous reports
(Za ´rate et al, 2007; Sharma et al, 2008), the reduced sample size
or the low incidence of some grade 3/4 toxicities may have
contributed.
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Figure 1 PFS Kaplan–Meier plot for PFS according to (A) the GSTP1-
grouped genotype and (B) the number of favourable factors (FF): 2 years
PFS for 0–1 FF, 0%; and 5 years PFS for 2–3 FF, 5 and 42%, respectively.
Table 4 Adjusted Cox multivariate analysis for PFS
Factor Variable n
PFS (median)
months
Hazard
ratio
a 95% CI P
Ko ¨hne Low 26 15 1.0 Reference 0.009
Intermediate 28 9.8 2.5 1.2–5.1
High 6 3.2 15.9 4.3–59.1
CA
b No 30 6.5 10.7 4.6–25.1 0.001
Yes 28 16.8 1.0 Reference
GSTP1 AA 20 6.3 2.6 1.3–5.4 0.008
AG+GG 40 12.7 1.0 Reference
Abbreviations: CI¼confidence interval; GSTP1¼glutathione-S-transferase Pi;
HR¼hazard ratio; PFS¼progression-free survival.
aHR adjusted by significant
genotypes (univariate analysis), Ko ¨hne classification.
bConsolidation approach after
triplet treatment.
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British Journal of Cancer (2010) 102(6), 987–994 & 2010 Cancer Research UKThe very significant long-term follow-up of our trial and the
use of both clinical and molecular parameters may allow
identification of patients who may benefit most from the
up-front use of this triplet regimen. Confirmation of these
findings, and particularly the very favourable outcome of
patients with GSTP1-AG/GG, Ko ¨hne low-risk category and
consolidation therapy with liver surgery, warrants further
research.
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